Author: Bioxytran Inc.

Posted Date:

March 2, 2026

Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19

Bioxytran Inc.

March 2, 2026
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran

Bioxytran Inc.

February 11, 2026
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics

Bioxytran Inc.

February 2, 2026